ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona
Daiichi Sankyo at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
Daiichi Sankyo takes part in 3 sessions at ESMO 2026 in Madrid, and exhibits at Booth 8033. Its program centres on antibody-drug conjugates in breast and lung cancer, including the role of nurses in caring for patients with advanced breast cancer. It also covers identifying patients with non-small cell lung cancer through actionable gene changes, and treatment of extensive-stage small cell lung cancer.
| Organization | ESMO 2026 Attendance |
|---|---|
Daiichi Sankyo Tokyo, Japan | |
Japanese pharmaceutical company developing antibody-drug conjugates including trastuzumab deruxtecan and datopotamab deruxtecan. | Booth Exhibiting at Booth 8033 Satellite Sun Oct 25 12:00–13:00 Daiichi Sankyo | AstraZeneca - Piecing together the ADC patient journey: The vital role of nurses in advanced breast cancer care Breast cancerNursing & supportive care Satellite Sun Oct 25 18:30–20:00 Daiichi Sankyo - Patient Identification in NSCLC: 10 From Actionable Genomic Alterations to Emerging ADC Opportunities Lung & thoracic cancersBiomarkers & precision oncology Satellite Mon Oct 26 13:00–14:30 Daiichi Sankyo and MSD - Shaping the Future of ES-SCLC: Pioneering Treatment Strategies Lung & thoracic cancers |
Find decision makers at Daiichi Sankyo
Tell us what you sell and we’ll find the people at Daiichi Sankyo most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction